Medicare Enrolled
Dr. Sumeet Chandra, M.D.
Hematology & Oncology · Melbourne, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chandra from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chandra? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chandra
Dr. Sumeet Chandra is a hematology & oncology in Melbourne, FL, with 19 years in practice. Based on federal Medicare data, Dr. Chandra performed 259,288 Medicare services across 2,921 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chandra received a total of $17,164 from 87 pharmaceutical and/or device companies across 896 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chandra is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 1% volume in FL$ $17,164 industry payments
Medicare Practice Summary
Medicare Utilization ↗259,288
Medicare services
Top 1% in FL for hematology & oncology
2,921
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~13,647 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 90,750 | $1 | $5 |
| Filgrastim injection (Nivestym) for white blood cells | 57,120 | $0 | $6 |
| Pembrolizumab injection (Keytruda) | 34,200 | $43 | $147 |
| Darbepoetin injection (Aranesp) for anemia | 19,000 | $2 | $21 |
| Denosumab injection (Prolia/Xgeva) | 18,060 | $18 | $70 |
| Anti-nausea injection (fosaprepitant) | 14,850 | $0 | $7 |
| Iron infusion (Monoferric) | 3,900 | $16 | $75 |
| Epoetin alfa injection (Procrit) for anemia | 3,560 | $6 | $55 |
| Dexamethasone injection (steroid) | 2,974 | $0 | $3 |
| Epoetin alfa injection (Retacrit) for anemia | 2,440 | $6 | $30 |
| Injection, granisetron hydrochloride, 100 mcg | 2,000 | $0 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,590 | $1 | $122 |
| Office visit, established patient (30-39 min) | 1,340 | $97 | $224 |
| Office visit, established patient (20-29 min) | 1,196 | $64 | $180 |
| Injection of additional new drug or substance into vein | 743 | $12 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 647 | $99 | $686 |
| Drug injection, under skin or into muscle | 575 | $11 | $93 |
| Injection, carboplatin, 50 mg | 402 | $2 | $300 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 373 | $54 | $270 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 363 | $47 | $304 |
| Injection, zoledronic acid, 1 mg | 341 | $7 | $472 |
| Infusion, normal saline solution , 1000 cc | 253 | $2 | $19 |
| Injection, diphenhydramine hcl, up to 50 mg | 217 | $1 | $7 |
| New patient office visit (30-44 min) | 207 | $83 | $230 |
| Administration of chemotherapy into vein, each additional hour | 199 | $22 | $156 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 171 | $1 | $19 |
| Injection of drug or substance into vein | 152 | $29 | $240 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 150 | $22 | $152 |
| Collection of blood sample from implanted device | 149 | $20 | $90 |
| Administration of additional new drug or substance into vein, 1 hour or less | 145 | $50 | $334 |
| Infusion into a vein for hydration, each additional hour | 144 | $10 | $73 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 138 | $135 | $3,938 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 112 | $1 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 94 | $25 | $249 |
| Blood draw (venipuncture) | 93 | $8 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 88 | $16 | $97 |
| Administration of additional new drug or substance into vein using push technique | 86 | $43 | $281 |
| Drawing of blood for a medical problem | 82 | $68 | $330 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 79 | $24 | $141 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 63 | $3 | $15 |
| Office visit, established patient, complex (40-54 min) | 51 | $137 | $360 |
| Irrigation of implanted venous access drug delivery device | 47 | $16 | $111 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 47 | $25 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 39 | $15 | $91 |
| New patient office visit (45-59 min) | 38 | $129 | $420 |
| Initial hospital admission, high complexity | 20 | $128 | $420 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
37.0% high complexity
61.6% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,164
Total received (2018-2024)
Avg $2,452/year across 7 years
Top 28% in FL for hematology & oncology
87
Companies
896
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,951 (98.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$213 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,020
2023$2,074
2022$2,860
2021$2,971
2020$2,308
2019$2,364
2018$2,566
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,576
PFIZER INC.
$1,352
Janssen Biotech, Inc.
$873
E.R. Squibb & Sons, L.L.C.
$867
Amgen Inc.
$833
AstraZeneca Pharmaceuticals LP
$832
Genentech USA, Inc.
$771
Celgene Corporation
$701
Merck Sharp & Dohme Corporation
$621
Seagen Inc.
$549
Merck Sharp & Dohme LLC
$547
Incyte Corporation
$498
Daiichi Sankyo Inc.
$486
Lilly USA, LLC
$485
Astellas Pharma US Inc
$462
GENZYME CORPORATION
$439
Takeda Pharmaceuticals U.S.A., Inc.
$370
Foundation Medicine, Inc.
$303
GlaxoSmithKline, LLC.
$283
Bayer HealthCare Pharmaceuticals Inc.
$258
Regeneron Healthcare Solutions, Inc.
$235
BeiGene USA, Inc.
$212
Pharmacyclics LLC, An AbbVie Company
$189
Boehringer Ingelheim Pharmaceuticals, Inc.
$186
Eisai Inc.
$173
Kite Pharma, Inc.
$137
Karyopharm Therapeutics Inc.
$131
Ipsen Biopharmaceuticals, Inc
$130
Gilead Sciences, Inc.
$129
JAZZ PHARMACEUTICALS INC.
$119
Taiho Oncology, Inc.
$118
AngioDynamics, Inc.
$103
ARRAY BIOPHARMA INC
$101
Puma Biotechnology, Inc.
$100
TAIHO ONCOLOGY, INC.
$99
Bayer Healthcare Pharmaceuticals Inc.
$96
Pharmacosmos Therapeutics Inc.
$86
Deciphera Pharmaceuticals Inc.
$75
SOBI, INC
$70
Seattle Genetics, Inc.
$64
AMAG Pharmaceuticals, Inc.
$59
Helsinn Therapeutics (U.S.), Inc.
$58
PUMA BIOTECHNOLOGY, INC.
$56
AbbVie, Inc.
$53
Kyowa Kirin, Inc.
$50
SERVIER PHARMACEUTICALS LLC
$50
CSL Behring
$47
AbbVie Inc.
$46
ADC Therapeutics America, Inc.
$44
Pharmacyclics LLC, an AbbVie Company
$44
G1 Therapeutics, Inc.
$43
Legend Biotech USA Inc.
$43
Rigel Pharmaceuticals, Inc.
$43
Jazz Pharmaceuticals Inc.
$41
Acceleron Pharma, Inc.
$40
EISAI INC.
$39
Global Blood Therapeutics, Inc.
$38
Advanced Accelerator Applications
$36
Clovis Oncology, Inc.
$36
GE HealthCare
$34
CTI BioPharma Corp.
$33
MorphoSys, US Inc.
$31
TerSera Therapeutics LLC
$30
PharmaEssentia USA Corporation
$29
Genmab U.S., Inc.
$27
Verastem, Inc.
$27
Alnylam Pharmaceuticals Inc.
$26
Mirati Therapeutics, Inc.
$26
Secura Bio, Inc.
$25
Servier Pharmaceuticals LLC
$25
ABBVIE INC.
$24
Stemline Therapeutics Inc.
$24
TESARO, Inc.
$24
EMD Serono, Inc.
$23
Heron Therapeutics, Inc.
$21
Sun Pharmaceutical Industries Inc.
$20
TG THERAPEUTICS, INC.
$20
Innate Pharma, Inc
$20
Blueprint Medicines Corporation
$20
Sumitomo Pharma America, Inc.
$19
Alexion Pharmaceuticals, Inc.
$19
Exelixis Inc.
$18
Epizyme, Inc.,
$17
TOLMAR Pharmaceuticals, Inc.
$15
Dova Pharmaceuticals
$14
Janssen Pharmaceuticals, Inc
$14
Agios Pharmaceuticals, Inc.
$12
Top 3 companies account for 22.1% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · Epkinly · FARYDAK · FERAHEME · FOUNDATIONONE · FRUZAQLA · Farydak · GAZYVA · GILOTRIF · GIVLAARI · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INVOKANA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LUMOXITI · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lumoxiti · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRBETRIQ · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Phesgo · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Reblozyl · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · UKONIQ · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · Vyloy · XALATAN · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · Zemaira · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
12
Per 100K population
1.9
County median income
$75,817
Nearest hospital
ORLANDO HEALTH MELBOURNE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Chandra is a mixed practice specialist, with above-average Medicare volume (top 1% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Chandra experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Chandra performed 90,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chandra receive payments from pharmaceutical companies?
Yes. Dr. Chandra received a total of $17,164 from 87 companies across 896 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chandra's costs compare to other hematology & oncologys in Melbourne?
Dr. Chandra's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chandra) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Melbourne
Browse hematology & oncologys in Melbourne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology